investment analyst coverage

The company holds a leading position in reproductive testing and is expected to rapidly grow its oncology business to address a total market of $21 billion.

The investment bank said that the company's noninvasive genomic test for melanoma detection could capture a large market currently served by invasive biopsies.

The investment bank said it believes OraSure will obtain an FDA Emergency Use Authorization for its COVID-19 antigen test that could lift its stock price.

Wall Street analysts are bullish on the firm's cell selection platform technology, which could find a total addressable market of more than $20 billion.

The coverage comes after the women's health diagnostics firm went public last month, seeking up to $100 million in the offering.

The investment bank said CareDx's products are gaining traction and that the stock is positioned for 20 percent to 30 percent growth over the next few years.

The investment bank gave shares of the Temple City, California-based genetic testing company a buy rating and a $20 price target.

The investment bank said the company's molecular diagnostics have the potential to replace microarrays for cytogenetics analysis.

The investment bank said that Exact's Cologuard test continues to gain market share, and that its alternatives are largely invasive and inferior.

The investment banking firm has lowered its rating for shares of the sequencing giant, but raised its price target to $340 from $330.